Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Atrial fibrillation, or A-fib, is an irregular heart rhythm that increases a person's risk of stroke, heart failure and even ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue ...

Background Atrial fibrillation (AF) and acute myocardial infarction (AMI) share risk factors and are bidirectionally associated. Several studies found higher risks of outcomes in individuals with both ...

The results will support the company’s application for expanded labeling of its popular Farapulse pulsed field ablation ...

Dr. Ron Aviles explains available procedures and recovery time for those with heart and vascular conditions. Sponsored by Overlake Medical Center and Clinics.

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...